Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701572 | Journal of Thoracic Oncology | 2017 | 19 Pages |
Abstract
Afatinib may be a beneficial therapeutic option for a subset of patients with lung cancer who harbor rare EGFR mutations in their tumors. Understanding how uncommon mutations affect protein structure and TKI binding will be important for identifying effective targeted therapies for these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jamie A. PhD, Lynette M. MD, Pasi A. MD, PhD,